From Medscape Diabetes & Endocrinology

Coverage from the

American Diabetes Association (ADA) 81st Scientific Sessions

June 25 - 29, 2021; Virtual

June 25 - 29, 2021 Virtual

ADA 2021 What's Best for Diabetes After Metformin? GRADE Outdated at Outset The GRADE trial compared four different agents as add-ons to metformin for type 2 diabetes, and while liraglutide and insulin glargine fared best, the study is already outdated, said one commentator.
Medscape Medical News, June 30, 2021
ADA 2021 AMPLITUDE-O: Efpeglenatide Benefits in High-Risk Diabetes In older patients with long-time type 2 diabetes and CVD or kidney disease, the investigational GLP-1 agonist efpeglenatide was safe and lowered the risk of CV events in AMPLITUDE-O.
Medscape Medical News, June 29, 2021
ADA 2021 More Data Link Unmanaged Diabetes, High Glucose to Severe COVID-19 More findings suggest that hospitalized patients with COVID-19 need aggressive treatment of hyperglycemia, regardless of the diagnosis of diabetes.
Medscape Medical News, June 27, 2021

Conference News

ADA 2021 Testosterone Therapy for Hypogonadism With Diabetes?
Medscape Medical News, August 2, 2021
ADA 2021 New Agents for Youth-Onset Type 2 Diabetes 'Finally in Sight'
Medscape Medical News, July 13, 2021
ADA 2021 Do Anti-VEGF Injections for Diabetic Retinopathy Impact Mortality?
Medscape Medical News, July 8, 2021
ADA 2021 Not So Crazy: Pancreas Transplants in Type 2 Diabetes Rising
Medscape Medical News, July 8, 2021
ADA 2021 Insulin Degludec Better Than Glargine for Nighttime Hypos in T1D
Medscape Medical News, July 6, 2021
ADA 2021 Insulin-Pramlintide Combo Improves Type 1 Diabetes Control
Medscape Medical News, July 6, 2021
ADA 2021 Diabetes Could Be Main Factor Behind Accelerated Progression of COVID-19
Reuters Health Information, July 5, 2021
ADA 2021 Digital Diabetes Coaching Systems: Too Expensive or Worthwhile?
Medscape Medical News, July 5, 2021
ADA 2021 'Praise Diabetes': Project in Black Churches Improves A1c
Medscape Medical News, July 2, 2021
ADA 2021 Spinal-Cord Stimulation Provides Durable Relief of Painful Diabetic Neuropathy
Reuters Health Information, July 1, 2021
ADA 2021 SUSTAIN FORTE: 2-mg Semaglutide Bests 1 mg in Type 2 Diabetes
Medscape Medical News, July 1, 2021
ADA 2021 ADA Guidance: Bring Type 1 Diabetes in Adults Out of the Shadows
Medscape Medical News, July 1, 2021
ADA 2021 What's Best for Diabetes After Metformin? GRADE Outdated at Outset
Medscape Medical News, June 30, 2021

ADA 2021 Garage Lingo Boosts Diabetes Self-care in Mexican Men
Medscape Medical News, June 30, 2021
ADA 2021 AMPLITUDE-O: Efpeglenatide Benefits in High-Risk Diabetes
Medscape Medical News, June 29, 2021
ADA 2021 Implanted Glucose Monitor for Diabetes Accurate Up to 6 Months
Medscape Medical News, June 28, 2021
ADA 2021 Semaglutide 2.4 mg 'Ushers in a New Era in Medical Obesity Care'
Medscape Medical News, June 28, 2021
ADA 2021 Improving Access to Care for Minority Youth With Type 1 Diabetes
Medscape Medical News, June 28, 2021
ADA 2021 Amputation Rates in Diabetes Fall in Sweden, Rise in the US
Medscape Medical News, June 28, 2021
ADA 2021 More Data Link Unmanaged Diabetes, High Glucose to Severe COVID-19
Medscape Medical News, June 27, 2021
ADA 2021 Omnipod 5 'Artificial Pancreas' Shows Benefit in Type 1 Diabetes
Medscape Medical News, June 27, 2021
ADA 2021 'Stunning' Twincretin Beats Semaglutide in Type 2 Diabetes
Medscape Medical News, June 27, 2021
ADA 2021 Time-Restricted Eating Is 'Promising, But More Data Are Needed'
Medscape Medical News, June 26, 2021
ADA 2021 'Staggering' Doubling of Type 2 Diabetes in Kids During Pandemic
Medscape Medical News, June 26, 2021
ADA 2021 ADA Scientific Sessions Address the Old and the New
Medscape Medical News, June 22, 2021

Popular News from ADA 2020

SGLT2 Inhibitors Now 'Belong to Cardiologists and Nephrologists' Physicians of different specialties are still getting used to the idea that SGLT2 inhibitors aren't just for diabetes anymore.
Medscape Medical News, Jul 16, 2020
Early Data on Once-Weekly Insulin; Will it Transform Treatment? With similar efficacy and safety to insulin glargine U100, if findings are confirmed in phase 3 and product is approved, it could be the first-ever weekly insulin.
Medscape Medical News, Jun 15, 2020
VERTIS-CV: Late-Comer Ertugliflozin Shows HF Benefit Only in CVOT The findings are consistent with previous cardiovascular outcome trials of other SGLT2 inhibitors in type 2 diabetes, says an expert.
Medscape Medical News, Jun 18, 2020

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

CGM in Hospitals as Standard of Care: What Have We Learned?
Athena Philis-Tsimikas, MD; Mark Harmel, MPH
New FDA Guidance on T2D Trial Design Provides Flexibility
John B. Buse, MD, PhD; Mark Harmel, MPH
With Tirzepatide, a 'Great Future' for Patients With T2D
Juan P. Frias, MD; Mark Harmel, MPH
Top Studies, Highlights From ADA 2021
Harpreet S. Bajaj, MD, MPH; Akshay B. Jain, MD
After Metformin, Which Drug Makes the GRADE?
Deborah J. Wexler, MD, MSc; Mark Harmel, MPH
The Best Way to Prevent Type 2 Diabetes? Change Our Target
Hertzel C. Gerstein, MD; Mark Harmel, MPH
Understanding COVID and Diabetes: Ominous Findings, Next Steps
Edward W. Gregg, PhD; Mark Harmel, MPH
Agents of Change: 4 Ways to Battle Social Determinants of Health
Shivani Agarwal, MD, MPH; Mark Harmel, MPH
New Guidelines for Type 1 Diabetes in Adults: An Overview
Anne L. Peters, MD

Previous Coverage